Aurora Cannabis Inc. has urged shareholders to take no action after Curaleaf Holdings Inc. formally launched an unsolicited takeover bid, escalating a dispute between two of the cannabis industry’s largest operators.
The August 19 offer values Aurora shares at an implied US$4.00 each. Curaleaf is proposing to pay 0.3463 of a subordinate voting share plus US$0.75 in cash for each Aurora share.
The offer also caps the value of the consideration at US$5.00 per Aurora share. Aurora highlighted that this ceiling remains below levels at which its shares traded as recently as December 18, 2025.
The hostile bid puts Aurora’s valuation and international medical cannabis assets firmly in focus while introducing uncertainty over the company’s ownership and strategic direction.
Aurora Says Curaleaf Is Seeking Its Assets at a Low Valuation
Aurora characterized Curaleaf’s decision to take the proposal directly to shareholders as an attempt to pressure investors into accepting a short-term outcome.
Executive Chairman and CEO Miguel Martin said Aurora believes Curaleaf wants to acquire its EU-GMP manufacturing facilities and global medical cannabis platform “at the lowest price possible.”
Aurora also disputed Curaleaf’s characterization of its business performance, arguing that it doesn’t reflect the company’s recently reported quarterly results or its stated European medical cannabis strategy.
The valuation disagreement is particularly relevant to shareholders because Aurora views its international medical operations as assets capable of generating additional future value. Accepting Curaleaf’s bid would effectively transfer that potential upside to the combined company in exchange for the cash-and-stock consideration offered yesterday.
Because most of the proposed consideration consists of Curaleaf shares, Aurora investors would also retain exposure to the cannabis sector through Curaleaf if the transaction succeeds. However, the ultimate value received would partly depend on Curaleaf’s share price, subject to the US$5.00-per-share cap.
Dispute Emerges Over Previous Takeover Discussions
Aurora also pushed back against suggestions that it had been unwilling to engage with Curaleaf before the hostile offer.
The company said discussions between the two sides date back to June 22, 2026, with the most recent engagement taking place on August 12.
Aurora previously received letters from Curaleaf dated June 23 and July 7 outlining potential acquisition proposals. According to Aurora, the first contained no proposed financial terms, while the second did not specify the proposed mix of cash and stock consideration.
Curaleaf announced its intention to make an offer on August 11 before formally commencing the unsolicited bid.
The competing accounts add another layer for investors assessing whether Curaleaf’s current proposal represents an attractive takeover premium or undervalues Aurora’s longer-term prospects.
Aurora Board Forms Special Committee to Review Bid
Aurora’s board has not yet recommended whether shareholders should accept the offer.
Instead, it has formed a special committee composed of independent directors to evaluate Curaleaf’s proposal with its advisors. Aurora expects to issue a more comprehensive response, with shareholders set to receive the board’s formal recommendation through a news release and Directors’ Circular within 15 days, in accordance with applicable securities laws.
Until then, Aurora is explicitly advising shareholders not to tender their shares.
There is no immediate deadline requiring a decision. The offer must remain open for at least 105 days, giving Aurora shareholders until at least December 1, 2026, to consider the proposal.
What the Curaleaf Bid Means for Aurora Stock
The hostile offer sets a clear reference point for Aurora’s valuation at an implied US$4.00 per share while drawing greater investor attention to the value of the company’s European and international medical cannabis operations.
It also creates several variables that could influence Aurora shares over the coming months. Investors will be watching the board’s formal recommendation, Aurora’s arguments on standalone value, movements in Curaleaf’s stock price, and whether the terms change.
Aurora’s emphasis on the US$5.00 consideration cap and its historical share price suggests valuation will be central to its defense against the takeover.
For Curaleaf shareholders, meanwhile, the proposed transaction would provide exposure to Aurora’s EU-GMP infrastructure and international medical cannabis platform. However, the acquisition would require issuing Curaleaf shares alongside the cash component.
With Aurora’s board still reviewing the bid, the takeover process remains unresolved. The next major development for investors will be the company’s formal recommendation and detailed assessment of whether Curaleaf’s US$4.00 implied offer adequately reflects Aurora’s current and future value.
Rita Ferreira
Rita is a seasoned writer with over five years of experience, having worked with globally renowned platforms, including Forbes and Miister CBD. Her deep knowledge of hemp-related businesses and passion for delivering accurate and concise information distinguish her in the industry. Rita's contributions empower individuals and companies to navigate the complexities of the cannabis world, and her work remains a valuable resource for those seeking a deeper understanding of its potential.
